Rociletinib Withdrawn Phase 2 Trials for Non-Small Cell Lung Cancer (NSCLC) / Non-Small Cell Lung Carcinoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02705339Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)